SCIENTIA IN THE NEWS
Money Health: Go East, Young Man?Brendon Nafziger, Writer, DOTmedMarch 8, 2010 In this DOTmed article where Harry Glorikian, Scientia Advisors’ managing partner, is extensively quoted, Brendon Nafziger addresses the following timely question: Is China's mega 850-billion-yuan health care stimulus plan, coupled with a massive population beginning to succumb to Western diseases, a miracle for U.S. medical device makers, or a mirage? The article briefly discusses China’s health care stimulus plan and demand drivers, and point to issues companies wishing to enter the Chinese market may face, including domestic competition for medical devices, local laws and customs, as well as sustainability. This report originally appeared in the February 2010 issue of DOTmed Business News |
Growth Spurts Ahead for China's IVD, HIT MarketsBrendon Nafziger, Writer, DOTmedFebruary 25, 2010 In this DOTmed article, Nafziger highlights the release of Scientia Advisors’ Industry Review entitled “Healthcare Market in China”. China is embarking on a multi-trillion Yuan project to ensure health care coverage of all its citizens while bringing its creaky health system into the 21st century. The article, based on the study’s findings and an interview with Harry Glorikian, Scientia’s managing partner, explains how massive an undertaking it truly is, and how much healthcare IT and diagnostics stand to benefit from the coming cash bonanza. |
Report: China’s healthcare spending to reach $600B by 2015Omar Ford, Medical Device Daily Staff WriterFebruary 12, 2010 In this Medical Device Daily Article, Omar Ford, introduces a recent study by Scientia Advisors on the healthcare system in China which is likely to see big changes over the next few years. Driven by the government's 3 year reform plan to improve healthcare services, Harry Glorikian, managing partner at Scientia Advisors, states that "these updates to China’s healthcare system will help solidify the nation’s outdated system and have a tremendous impact on the economy." The article also highlights some of the major segments of growth such as the medical device, in vitro diagnostics and healthcare IT market areas. |
Drug Companies Likely To Stay Cautious On Large Biotech Deals - Dow Jones articleTom Gyrta , Dow JonesJanuary 15, 2010 In this article, based on interviews with Scientia Advisors Managing Partner Harry Glorikian, Mervyn Turner, chief strategy officer of Merck & Co (MRK), and others, Dow Jones reporter Tom Gyrta concludes that while biotechnology drugs will continue to be of interest to drug companies, "risk averse pharmaceutical giants" are likely to "remain cautious" about large biotech deals. In the article, Glorikian points out that "pharmaceutical companies are hesitant to spend too much for technology with which they have limited experience and which is expensive to develop. They are easing into it." What is more, he says, recent manufacturing problems at Genzyme Corporation (GENZ) have made pharma companies wary of biotechnology's complexities in comparison with the simpler production of chemical pharmaceuticals taken in pill form. As a compromise, many Scientia pharmaceutical clients are looking into "biosimilars"--generic versions of biotechnology drugs--to reduce development risk. The article also describes recent biotech deals, buyout speculation regarding companies with potential blockbuster products, and companies' concerns about possible overspending, regulatory risk and uncertain market adoption. |
Biotech IPOs on the rise in MassJulie M. Donnelly, Mass High TechJanuary 14, 2010 Following a lengthy, quiet period for biotech initial public offerings (IPOs), activity has been picking up nationwide with four successful biotech IPOs in the second half of 2009. In Massachusetts, two Cambridge-based companies have recently registered for initial public offerings. In this article, Harry Glorikian, managing partner of Scientia Advisors, comments on the timing of one of these recent IPOs: “Aveo Pharmaceuticals filed for an IPO when the time was ripe. These deals allowed the company to develop its platform technology using capital from partnerships, rather than from issuing a premature IPO when the company and technology were still in their infancy.” |
Scientia in Federal Computer Week - Government Funding, Technological Advances Transform HealthcareBarbara DePompa,January 4, 2010 An evolution is taking place with health IT beginning to be part of the culture for providing healthcare. This article highlights Scientias’ market projection for health IT to support the evidence of the current growth wave: “Health IT will grow at a combined annual growth rate of 11 percent through 2013, according to consulting firm Scientia Advisors. The firm projects health IT will be the fastest growing segment of the $1 trillion global healthcare market, expanding from $35 billion in 2008 to more than $60 billion by 2013.” The author goes on explaining how many key technological tools and/or services are contributing to the current growth wave, in addition to government funding. |
HIT Fastest Growing Segment of Global Health Care MarketAdvance for Health Information ExecutivesDecember 24, 2009 In this Advance article, the release of Scientia Advisors' Health Information Technology (HIT) Industry Review is highlighted, including its findings that HIT is the fastest growing segment of the $1 trillion global health care market, and that its double-digit annual growth rate is likely to continue through 2013. Harry Glorikian, managing partner, is quoted stating that "Historically, therapeutics and medical devices have captured more than 90 percent of the worldwide health care product sales. But, with declining marginal benefits from new interventional products and greater emphasis on appropriate use of existing interventions, we project accelerating HIT-related sales." The article also points to key trends and growth drivers. |
State of the Industry ReviewRebecca Wright, Nutraceuticals WorldDecember 1, 2009 In this article, executives reflect on the past year in nutraceuticals and look ahead to what the future might bring. Bob Jones, Principal at Scientia Advisors, leads with the following insight on the state of the industry: “A few years ago, when I talked with major food companies about functional ingredients, what I mostly saw was polite interest, but no real commitment. That is, everyone acknowledged making products that promoted health was a virtuous endeavor, but very few felt an urgent need to take the plunge. That’s beginning to change. We now see major companies throughout the value chain committing real resources—staff, time and money—to creating ingredients and finished goods that provide a health benefit beyond basic nutrition. And some are putting products into the marketplace. We may be approaching a ‘tipping point’.” |
H1N1 Boosts Development in Pharma Sector - Many Factors, Chief Among Them a Potential Pandemic, Are Fueling Vaccine ResurgenceRod Raynovich, Genetic Engineering & Biotechnology NewsDecember 1, 2009 The potential H1N1 pandemic has drawn renewed interest in vaccines. This article by Rod Raynovich in Genetic Engineering & Biotechnology News reviews the vaccine market, its major players and the emerging companies with new technologies. Scientia Advisors' global vaccines market annual growth forecast of 12% from 2008 through 2014 is cited in the article, as well as the company’s growth projections in the viral and the pediatric bacterial vaccine sectors. |
HIT to Become a $60 B Market by 2013Brendon Nafziger, Writer, DOTmedNovember 11, 2009 In this DOTmed article, Nafziger highlights the release of Scientia Advisors' Health Information Technology (HIT) Industry Review. The HIT market is on the fastest growing markets in healthcare today with $35Bn today, growing at 11% to reach $60Bn in 2013. Much of the drive for HIT adoption stems from the government incentives put in place in an effort to improve healthcare. Harry Glorikian, managing partner, is quoted, "Hospitals are adopting them at various levels. It's becoming a must-have." The article points of some of the key insights in the review such as the rise of HIT in emerging economies like China, and the potential of the clinical decision support system (CDSS) market. |
Boom Times For Health IT Sector: The healthcare IT marketplace is growing by 11% annually, which will likely continue through 2013, says a study from Scientia AdvisorsMitch Wagner, Information WeekNovember 11, 2009 In this Information Week article, Wagner highlights the release of Scientia Advisors' Health Information Technology (HIT) Industry Review. The HIT market is on the fastest growing markets in healthcare today, showing 11% growth. The article points out some of the key insights in the review including the need for in-patient and out-patient EHRs, market dynamics, buying preferences of hospitals and key growth segments such as CDSS. |
Healthcare Finance News--Consultant: Healthcare IT market to grow 11 percent per year through 2013Bernie Monegain, Contributing Editor, Healthcare Finance NewsNovember 10, 2009 In this Healthcare Finance News article, Monegain highlights the release of Scientia Advisors' Health Information Technology (HIT) Industry Review. The HIT market is on the fastest growing markets of the $1Tn healthcare market today and growing at 11% to 2013. Harry Glorikian, managing partner, is quoted, "Historically, therapeutics and medical devices have captured more than 90 percent of worldwide healthcare product sales. But with declining marginal benefits from new interventional products and greater emphasis on appropriate use of existing interventions, we project accelerating HIT-related sales." The article points out some of the key insights in the review including the demand for in-patient and out-patient EHRs, market dynamics, buying preferences of hospitals and key growth segments such as CDSS. |
Cosmetics Design--Massive growth in cosmeceuticals leads to ingredients shortageSimon Pitman, Cosmetics DesignNovember 9, 2009 In this Cosmetics Design article, Pitman highlights the cosmeceuticals market and the need in this market for new innovative ingredients. He sources this conclusion from Scientia Advisors' recent release of a Cosmeceuticals market industry review, pointing out that the category is growing at twice the pace of the cosmetics industry in both the US and worldwide, but the development of technologically advanced active ingredients is not keeping up with the growth. He also highlights some of market dynamics in changing consumer trends, geographic breakdown and government regulation. |
The London Independent--As populations age, demand for 'cosmeceuticals' expected to riseThe London IndependentNovember 6, 2009 This London Independent article highlights the release of Scientia Advisors' new cosmeceuticals market industry review. Cosmeceuticals which are cosmetics which provide health benefits, is highlighted in the review as a fast growing area of personal care products. Within it, skincare is one of the fastest growing segments. Overall demand for these products are expected to increase as a age-conscious populations begin to age. |
Medical Device Daily--Scientia Study shows selfcare growing for delivery devicesOmar Ford, Staff Writer, Medical Device DailyNovember 5, 2009 In this Medical Device Daily article, Omar Ford highlights the release of Scientia Advisors' new parenteral market industry review. He explains that parenterals, which is a method of mechanically delivering drugs, is a $11.8Bn market growing at 7% to 2012. Within parenterals, the article highlights key insights from the review on the high growth in the consumer sector due to the increase in home health, the potential for this to decrease overall healthcare spending and even the migration of these technologies from the healthcare to nutrition. |
Featured Article: PharmacogenomicsJeffrey M. Perkel, BiocompareNovember 2, 2009 In this Biocompare article, Jeffrey Perkel provides an overview of what pharmacogenomics is. The name of branch of genetics has received significant hype over the last decade and it's definition has also expanded considerably. It has become to mean the use of various biomakers (DNA, RNA, protein) in diagnostics in order to predict positive response or adverse reaction to a pharmaceutical drug."It's the use that's classifying it, not the word genomic," explains Harry Glorikian, managing partner at Scientia Advisors. Perkel highlights many of the pharmacogenomic tests that are currently available and their performance in healthcare. He concludes that despite the current lack of pickup of the industry, the future of pharmacogenomics is positive. |
Confusing Choices for Doctors and Type 2 Diabetes Patients:
Patricia F. Dimond Ph.D., Genetic Engineering & Biotechnology News |
Scientia comments on vaccine industry for CBS Evening NewsJim Axelrod, CBS NewsOctober 22, 2009 Harry Glorikian, managing partner at Scientia Advisors along with other experts in the healthcare industry such as Dr. Martin Blaser, Chair of Medicine at NYU Langone Medical Center and Daniel Adams, CEO of Protein Sciences Corp comment on the H1N1 vaccine in Jim Axelrod's CBS Evening News report. |
Boston Globe--For drug makers, a shot in the arm: The quest for an H1N1 vaccine has been good business for some firmsRobert Weisman, Boston GlobeOctober 21, 2009 In this article, Robert Weisman delves into impact of the H1N1 vaccine push has had on vaccine-makers such as Novartis. He points out that in addition to the actual revenue garnered from the vaccine, the headway made in developing new research and streamlining of the production of vaccines, either by organic growth or acquisition, will be beneficial to the companies in future vaccine development. Scientia Advisors' global vaccines market projections, from $16 billion in 2007 to $35 billion in 2014, is cited in the article. Scientia Advisors' Managing Partner, Harry Glorikian was also quoted in the article pointing out the potential opportunity for vaccine makers in China which is planning on a national vaccine program. |
Fierce Vaccines--Swine flu hands vax industry $7B windfallJohn Carroll, Fierce VaccinesOctober 21, 2009 In this article, John Carroll highlights the potential $7 billion windfall reported by the Boston Globe. Scientia Advisors' estimate of the vaccine market is also highlighted in the Boston Globe article as jumping from $16 billion in 2007 to $35 billion in 2014. |
GenomeWeb--CombiMatrix Hires Baird to Provide 'Strategic Advice' in Buyers' MarketGenomeWeb Staff, GenomeWebSeptember 22, 2009 This article in GenomeWeb, focuses on the CombiMatrix and its recent decision to hire an investment bank, Baird to outline its future strategy. Harry Glorikian, managing partner at Scientia Advisors, is quoted in the article offering insight into the existing market situation stating that, "There are two ways to get yourself out of this existing market situation and one of them is to make very strategic smart acquisitions at good valuation that, as the market starts to turn, give you the ability to step out there." |
GenomeWeb: ProteoMonitor--Recent Deals Suggest Proteomics, Life-Science Markets May be Poised to Renew M&A ActivityProteoMonitor Staff, GenomeWebSeptember 21, 2009 This ProteoMonitor article highlights the recent surge of M&A activity in the proteomics markets which has suggested to many, a trend towards consolidation. The article highlights two deals in particular: a bid by Danaher to buy ABI/MDS mass-spec joint venture and MDS Analytical Technologies, and Agilent's bid for Varian. Scientia Advisors managing partner, Harry Glorikian is quoted in the article providing some insight into the drivers behind these acquisitions; pointing out potential growth opportunities that these acquisitions open up for the companies. |
GenomeWeb: ProteoMonitor--Tale of Danaher: From Crippled Real Estate Investment Trust to Mass Spec Top BananaTony Fong, GenomeWebSeptember 16, 2009 In this ProteoMonitor article, Tony Fong offers some details into Danaher, who's recent bid to buy the ABI/MDS mass-spec joint venture and MDS Analytical Technologies has vaulted it into the spotlight. Fong outlines the history and background of Danaher and the significant moves that it's made to build up its life sciences business over the last few years. Harry Glorikian, managing partner at Scientia Advisors was quoted stating "They're not making small moves. They're making very bold moves that give them a solid position within a growth market." |
Biomedical Business & Technology--Harry Glorikian, Consulting firm founder, Helping mold the future for med-tech firmsJim Stommen, Contributing Editor, Biomedical Business & TechnologySeptember 1, 2009 In this Biomedical Business & Technology (BB&T) article, Jim Stommen, interviews Harry Glorikian, founder and managing partner of Scientia Advisors. In the interview, Stommen probes many of the high profile issues in healthcare today including venture capital investments since the crisis, healthcare reform and what it means in terms of opportunities for companies, how companies should deal with the changing healthcare environment. The interview also goes into more detail about the diagnostics world, including molecular diagnostics, personalized medicine, imaging, and nanotechnology. |
LA Times--Medical testing in your home: Forget the office visit. Home-health exams can save time and money, and give patients some control.Kathleen Kelleher, LA TimesAugust 31, 2009 In this LA Times article, Kathleen Kelleher focuses on the developing new market of home or direct to consumer diagnostic testing. These tests are available for the consumer to directly purchase it from a lab or pharmacy and the results are then provided to the consumer. This reduces the potential cost of a doctor's visit and allows the patient to have more control and feel empowered about their health.Scientia Advisors, an international consulting firm is cited in the article sizing the potential market for this type of home health over-the-counter testing, which is growing at 7-8% a year. In addition to pointing out the potential of home testing, the article also stresses the importance to still get guidance on treatment from a doctor, especially for prescription medications. |
Medical Device Daily--Growing neurostimulation sector is opportunity for device makersLynn Yoffee, Medical Device DailyAugust 21, 2009 In this Medical Device Daily article, Lynn Yoffee announces the release of a new study by Scientia Advisors. The study focuses on the nascent neurostimulation market which currently, is growing at double digit growth rates. Harry Glorikian, managing partner at the firm, commented on this market stating that “It’s a new way of approaching the disease state – a solution that has eluded drugs and surgery.” The study highlights the significant potential of the neurostimulation market, which promises to circumvent a lot of the downsides that have plagued drugs and surgical treatment option such as nasty side-effects and irreversibility. The article highlights some of the details from the study such as the size and growth of the market as well as three largest segments of neurostimulation market. The study itself, which is expected to be released later this month, predicts positive outcomes for patients and device makers. |
The Marker -- Who will gain from the chronic problems of the US? (trans.)Paz Vaysman, The MarkerAugust 19, 2009 This article in The Marker, an Israeli news publication, focuses on the wound care market. It highlights the American healthcare reform and the problem hospitals are facing to find faster and cheaper solutions for wound care. Using a data from study by Scientia Advisors, the article highlights the steady growth of this market and potential opportunities in this market. The article also points out six Israeli companies concentrating in this area with descriptions of the company and key products: Lifewave, HealOr, MacroCure, Q Ray, MediWound, MediWound. |
Mass High Tech--Life sciences startups launching despite recessionJulie M. Donnelly, Mass High TechAugust 14, 2009 In this Mass High Tech article, Julie Donnelly focuses on the recent movement in the venture capital landscape. Despite the recession, several life science startups have launched and are thought to have a better shot at profitability. Harry Glorikian, managing partner at Scientia Advisors, points out that "The pace of deals is slower, but investors still have to put their money somewhere" and that firms are being creative in where they get their funds. The article highlights three companies: Acetylon Pharmaceuticals Inc., Forma Therapeutics Inc., and Targ-anox, Inc, who have been successful in getting funding, each in a different way. |
Medical Device Daily--Consulting firm head sees opportunity in reform effortJim Stommen, Medical Device Daily Contributing WriterJuly 28, 2009 In this Medical Device Daily article, Jim Stommen highlights several points made by Harry Glorikian, managing partner at Scientia Advisors, on the potential opportunity of the current market. In a wide-ranging question-and-answer interview session, which will be published at a later date, Glorikian comments on the perspective and approach that companies should have in managing product portfolios and development efforts in order to take advantage of the current economic crisis and reposition themselves for future growth. The full version of the interview session will be published in Medical Device Daily's sister publication, Biomedical Business & Technology in the September issue. |
Agilent Plans to Buy Varian for $1.5 Billion to Expand Footprint in Life SciencesTony Fong, Genome WebJuly 27, 2009 This Genome Web article covers Agilent's recent announcement to a spend $1.5 Bn to purchase Varian. Harry Glorikian, managing partner at Scientia Advisors, is quoted in the article with his view on the announcement. Glorikian states that the purchase will benefit Agilent by expanding its product portfolio but that the purchase's true value will be realised after Agilent successfully integrates the purchase and develops a strategy for its push into life sciences. |
Medical Device Daily--Scientia says opportunities abound in peripheral sectorJim Stommen, Executive Editor, Medical Device DailyJune 25, 2009 In this Medical Device Daily article, Jim Stommen puts the spotlight on a study performed by Scientia Advisors on the peripheral vascular disease (PVD) sector of the healthcare market. In it, Stommen points out some of the key takeaways from the study such as the high growth potential of several segments within the PVD market including chronic venous insufficiency (CVI) and thrombosis diagnosis and treatment. Harry Glorikian, Scientia's managing partner, is also quoted in the article pointing out that companies are missing potential opportunities: "Major companies are missing possibilities that could significantly improve the health and well-being of aging global populations, cut healthcare costs, and boost their own bottom lines." Scientia Advisors regularly conducts and publishes studies into market areas which have significant growth potential. These studies help Scientia deepen their understanding of different areas of healthcare which may have gone unnoticed by others. These studies also allow Scientia to enhance their process. A synopsis of the study referenced above can be found here. Other Scientia market overviews can be found here. |
Xconomy -- Biogen and Fellow Boston-Area Biotechs Ready for BiogenericsRyan McBride, XconomyJune 24, 2009 This Xconomy article, focuses on the dynamics of the growing biosimilars market. This nascent market is referred to by many names: biogenerics, bio-betters, and follow-on biologics, to name a few. Scientia Advisors' partner, Amit Agarwal, comments on the interest this market has drawn from companies with biologics capabilities: “What we’re seeing is that they are at least considering this market. It’s out there and it’s not just coming from the usual suspects.” The article also points out some of the key areas of debate surrounding this developing market and highlights some companies making moves in this space. |
BioWorld -- Patents: Lifeblood of Biotech or a Cancer to Innovation?Anette Breindl, BioWorld: Financial WatchMay 25, 2009 BioWorld's article addresses the controversy surrounding the patenting of human genes in light of the recent lawsuit by the American Civil Liberties Union and others against the Utah based biotech company Myriad Genetics and the University of Utah Reasearch Foundation. The lawsuit highlights an ongoing debate on whether or not the current patent system stifles or encourages innovation. Scientia Advisors' managing partner Harry Glorkian is quoted in the article, stating that “the point of filing is to make information public and encourage others” to use that information for further innovation. The article also highlights the actions of large pharma company GlaxoSmithKline to combat the decline in drug discovery innovation via collaborations and releasing information into the public domain. Some critics attribute the decline of innovation in drug discovery to the Bayh-Dole Act. Scientia’s Glorikian was quoted stating that he, as well as others at Scientia, “have never seen any data connecting the two,” and instead related the decline in drug discovery productivity to “a host of other factors” including patient stratification and a changing regulatory landscape." |
Science interviews Harry Glorikian in "Molecular diagnostics: Personalizing personalized medicine"Jeffrey M. Perkel, ScienceMay 8, 2009 The journal Science interviews Scientia's Harry Glorikian regarding developments within the molecular diagnostics arena. |
MDx will drive personalized medicineVicki Glaser, Genetic Engineering & Biotechnology NewsApril 1, 2009 Scientia Advisors discusses how diagnostics and innovation will play a role in reducing future healthcare costs. |
Scientia, a Life Sciences Management Consulting Firm, Provides Answers, Not QuestionsWade Roush, XconomyMarch 10, 2009 Wade Roush from Xconomy comments on what sets Scientia apart from other management consulting firms. |
The Wall Street Journal uses Scientia Advisors' medical device market growth estimatesAlicia Mundy, The Wall Street JournalMarch 6, 2009 In the article, "Political Lobbying Drove FDA Process," WSJ writer Alicia Mundy referenced market growth estimates derived by Scientia Advisors for the medical device industry. |
When drugs get personalMed Ad NewsFebruary 1, 2009 With the emergence of drug/diagnostic combinations, the issues surrounding the marketing of these products are increasingly becoming important to pharmaceutical companies. In this article, by Joshua Slatko, Scientia’s Amit Agarwal, provides insight into possible marketing strategies and the integral role of physicians in this effort. “This means that the market /sales effort must be about helping physicians understand the disease in all its variations and then educating physicians about clinical treatment guidelines,” he says. Additionally, Agarwal points to older, already marketed products, as having substantial potential for drug/diagnostic combinations and as being a cost effective way of boosting sales of already marketed drugs. Agarwal comments, “The diagnostic/drug approach is a very cost effective way to boost the sales of non-blockbuster drugs that the standard life-cycle management approaches (reformulation, indication expansion, and sales-force expansion) do not work well for.” |
Expert: Diagnostics could increase drugmakers' revenueBIO SmartBriefJanuary 14, 2009 Scientia's Amit Agarawal discusses how major pharmaceutical firms could increase their earnings and boost patient health by marketing diagnostic tools alongside their existing products. |
New Personalized Medicine Model ProposedUnited Press InternationalJanuary 13, 2009 Amit Agarwal, partner at Scientia Advisors, recommends new strategies for pharmaceutical firms seeking to find alternative uses for their already approved therapeutics. |
Bob Jones of Scientia Advisors Discusses the Growth of the Functional Foods MarketDan Mitchell, BNET FoodJanuary 5, 2009 Bob Jones, principal at Scientia Advisors, discusses important case studies and trends driving the growth of the functional foods market. |
Principal Bob Jones interviewed on Public Radio International's "The World"Lisa Mullins, PRI's The WorldJanuary 5, 2009 The use of so-called functional foods, is on the rise, especially in China and Japan. Functional foods are those fortified with additional vitamins or minerals. Anchor Lisa Mullins speaks with Bob Jones of the management consulting firm Scientia Advisors about why one country will accept a particular functional food and another will reject it. |
Scientia Forecasts Bright Future for Functional FoodsFood Product DesignDecember 18, 2008 Food Product Design interviews Bob Jones, principal at Scientia Advisors, on the reasons for growth within the functional foods market. |
Scientia Advisors Reports on the Future of Functional FoodsBoston Business JournalDecember 17, 2008 The Boston Business Journal highlights important insights made by Scientia Advisors on the growth of the functional foods market. |
Scientia Advisors Addresses the Impact of Decentralized Healthcare on the IVD IndustryQ1 ProductionsNovember 24, 2008 Harry Glorikian, managing partner at Scientia Advisors, highlights how the emergence of point-of-care centers will empower patient consumers and revolutionize the healthcare market, including the IVD industry. |
Scientia's Glorikian Discusses Next Generation Sequencers and their ApplicationsJustin Petrone, BioArray NewsNovember 4, 2008 Scientia Advisors speaks about applications for next generation sequencers and warns of threats these sequencers will pose to diagnostic businesses. |
Array-Based Dx Shops See Asia as One Promising Route to Global MarketplaceJustin Petrone, BioArray NewsNovember 4, 2008 European companies Mordiag and DiaGenic have announced tentative plans to pursue the launch array-based tests in China or India in addition to an initial launch in Europe. Harry Glorikian, managing partner at Scientia Advisors comments on this new push into these emerging markets. |
Scientia Advisors Discusses Microarrays, Molecular Dx, the Global Healthcare MarketBioArray NewsOctober 28, 2008 Harry Glorikian, managing partner at Scientia Advisors provides expert opinion and in-depth analysis on the array-based diagnostics market, elaborating on key trends and insights into the molecular diagnostics market. |
Scientia's Glorikian Comments on Invitrogen’s Acquisition of Applied BiosystemsGenomeWeb Daily NewsJune 12, 2008 Harry Glorikian, managing partner at Scientia Advisors, analyzes the merger between Invitrogen and ABI, noting that the life science tools market will remain competitive due to the presence of new technologies by smaller companies. |
Scientia Advisors Provides Insight into the Molecular Diagnostics Market as New Players EmergeCelia Lamb, Sacramento Business JournalJuly 20, 2007 Scientia Advisors describes the potential opportunity for genetic analysis tools companies within the molecular diagnostics market. |
Amid Molecular Dx Acquisition Trend, Some View Cepheid as Prime TargetEdward Winnick, GenomeWebJuly 11, 2007 Scientia Advisors highlight several companies that may be looking to move into the molecular diagnostics space via an acquisition of Cepheid because of its FDA-approved real-time PCR-based molecular diagnostics platform. |
Scientia's Agarwal Comments on the Strong Growth of Blood-Glucose Monitor CompanyRyan McBride, Mass High TechJune 24, 2007 Amit Agarwal, partner at Scientia Advisors, compares the strong performance of AgaMatrix to the overall diabetes monitoring market. |
Biogen plans in-house incubator to tap new productsRyan McBride, Mass High TechDecember 25, 2006 Scientia Advisor’s managing partner, Harry Glorikian, comments on Biogen Idec’s proposed strategy to form an incubator to develop an existing early start-up. |
Growth in Mass Spec Sales Helps Proteomic Market Grow Slow and Steady, Report FindsTony Fong, GenomeWebDecember 7, 2006 Harry Glorikian describes the drivers behind growth in the mass spectrometry market. |
Local conditions and national concerns within the European IVD marketJohn Conroy, IVD TechnologySeptember 1, 2006 Harry Glorikian, managing partner at Scientia Advisors, highlights specific drivers and trends affecting the European IVD market. |
What’s Next for Stem Cell Companies?Charles Jennings, Pharma Drug DiscoveryJuly 24, 2006 Scientia Advisors comments on the emerging field of cell-based therapy. |
Along with Growth Opportunities, Molecular Dx Market Likely to Bring a Wave of ConsolidationEdward Winnick, GenomeWebApril 12, 2006 Scientia Advisor’s managing partner, Harry Glorikian, forecasts a wave of M&A activity as larger companies seek to a build a molecular diagnostics portfolio. |
Roche's patent expiration opens US marketDrugResearcher.comMarch 30, 2006 Scientia Advisors managing partner, Harry Glorikian, describes how Roche’s patent expirations will affect companies such as Applied Biosystems. |
